BRPI0517843A - compostos de moléculas conjugadas com a atividade de absorção de células aumentada - Google Patents

compostos de moléculas conjugadas com a atividade de absorção de células aumentada

Info

Publication number
BRPI0517843A
BRPI0517843A BRPI0517843-6A BRPI0517843A BRPI0517843A BR PI0517843 A BRPI0517843 A BR PI0517843A BR PI0517843 A BRPI0517843 A BR PI0517843A BR PI0517843 A BRPI0517843 A BR PI0517843A
Authority
BR
Brazil
Prior art keywords
molecule
compounds
increased cell
absorption activity
cell absorption
Prior art date
Application number
BRPI0517843-6A
Other languages
English (en)
Inventor
Christophe Bonny
Didier Coquoz
Jianhua Chen
Original Assignee
Xigen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xigen Sa filed Critical Xigen Sa
Publication of BRPI0517843A publication Critical patent/BRPI0517843A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSTOS DE MOLéCULAS CONJUGADAS COM A ATIVIDADE DE ABSORçãO DE CéLULAS AUMENTADA. A presente invenção refere-se a uma molécula conjugada compreendendo pelo menos uma primeira porção (1) compreendendo uma sequência carreadora e pelo menos uma segunda porção (II) compreendendo pelo menos uma molécula de fármaco antitumor ou uma molécula de inibidor protease, a dita molécula conjugada compreendendo aminoácidos Denantioméricos em sua porção (1). Além disso, a invenção refere-se a composições farmacêuticas contendo a dita molécula conjugada bem como ao uso da dita molécula conjugada para tratamento terapêutico. Também são descritos métodos para melhorar a permeabilidade da célula ou solubilidade em água.
BRPI0517843-6A 2004-11-12 2005-11-09 compostos de moléculas conjugadas com a atividade de absorção de células aumentada BRPI0517843A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04026934A EP1656951A1 (en) 2004-11-12 2004-11-12 Conjugates with enhanced cell uptake activity
PCT/EP2005/011991 WO2006050930A2 (en) 2004-11-12 2005-11-09 Conjugates with enhanced cell uptake activity

Publications (1)

Publication Number Publication Date
BRPI0517843A true BRPI0517843A (pt) 2008-10-21

Family

ID=34927367

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517843-6A BRPI0517843A (pt) 2004-11-12 2005-11-09 compostos de moléculas conjugadas com a atividade de absorção de células aumentada

Country Status (10)

Country Link
EP (2) EP1656951A1 (pt)
JP (1) JP2008519785A (pt)
CN (1) CN101072589A (pt)
AR (1) AR051765A1 (pt)
AU (1) AU2005303949A1 (pt)
BR (1) BRPI0517843A (pt)
CA (1) CA2585421A1 (pt)
EA (1) EA200700976A1 (pt)
IL (1) IL182760A0 (pt)
WO (1) WO2006050930A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
NZ598159A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
DK2178549T3 (en) * 2007-07-26 2017-01-09 Revance Therapeutics Inc Antimicrobial peptide AND COMPOSITIONS THEREOF
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US8895497B2 (en) 2009-12-04 2014-11-25 Dcb-Usa, Llc Cathepsin S inhibitors
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
AU2010362444B2 (en) 2010-10-14 2015-08-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
JP6285447B2 (ja) * 2012-10-17 2018-02-28 ノヴォ ノルディスク アー／エス 経口ペプチド送達用の脂肪酸アシル化ｄ−アミノ酸
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
EA201501080A1 (ru) 2013-06-26 2016-07-29 Ксижен Инфлемейшн Лтд. Новое применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения различных заболеваний
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
AU2019228281B2 (en) * 2018-02-27 2024-06-13 Lipotrue, S.L. Peptides and compositions for use in cosmetics and medicine
CN108794581B (zh) * 2018-06-26 2021-09-10 江苏大学 一种靶向结合淋巴癌细胞系的特异性d型多肽及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152084A1 (en) * 2003-01-31 2004-08-05 Slattum Paul M. Compounds and processes for single-pot attachment of a label to nucleic acid
ES2210761T3 (es) * 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
WO2001013957A2 (en) * 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6610820B1 (en) * 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
AU2002240312A1 (en) * 2001-02-08 2002-08-19 Pankaj Paranjp Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
US20080090770A1 (en) * 2003-04-11 2008-04-17 Belmares Michael P Modulation of Muc1 Mediated Signal Transduction
AU2004235396B2 (en) * 2003-04-29 2010-11-25 Sarepta Therapeutics, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells

Also Published As

Publication number Publication date
AU2005303949A1 (en) 2006-05-18
JP2008519785A (ja) 2008-06-12
WO2006050930A2 (en) 2006-05-18
IL182760A0 (en) 2007-07-24
CA2585421A1 (en) 2006-05-18
WO2006050930A3 (en) 2007-04-26
CN101072589A (zh) 2007-11-14
EA200700976A1 (ru) 2007-12-28
EP1656951A1 (en) 2006-05-17
AR051765A1 (es) 2007-02-07
EP1809334A2 (en) 2007-07-25

Similar Documents

Publication Publication Date Title
CY1109722T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole
ATE524476T1 (de) Pyrazolopyrimidine als modulatoren von caseinkinase ii (ck2)
DK1521593T3 (da) Transdermale botulinumtoksinforbindelser
IL169896A0 (en) Methods and compositions for administering therapeutic and diagnostic agents
BRPI0613005A8 (pt) uso de polipeptídeos de aprotinina como veículos em conjugados farmacêuticos.
NZ543467A (en) The severe acute respiratory syndrome coronavirus
ATE252601T1 (de) Lang wirkende insulinotrope peptide
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
MX2007005644A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de cinasa.
BRPI0517458A (pt) derivados da xantina com atividade para o receptor hm74a
PE20061122A1 (es) Composiciones que incluyen hierro
EP1874793A4 (en) DISTRIBUTION OF SIRNA BY NEUTRAL LIPID COMPOSITIONS
BRPI0513850A (pt) composição terapêutica com uma neurotoxina botulìnica
WO2004031411A3 (en) Genes and polypeptides relating to human pancreatic cancers
UY31543A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
WO2009088838A3 (en) Triarylmethane analogs and their use in treating cancers
BR0305628A (pt) Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
AR051765A1 (es) Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas
Werle et al. Evaluation and improvement of the properties of the novel cystine-knot microprotein McoEeTI for oral administration
BRPI0514750A (pt) derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase
ATE458746T1 (de) Melphalan-derivate und ihre verwendung als chemotherapeutika gegen krebs
Hur et al. Effect of oligoarginine conjugation on the antiwrinkle activity and transdermal delivery of GHK peptide
WO2007064968A3 (en) Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
Suzuki et al. Anthraquinone derivatives as a new family of protein photocleavers
DE60318585D1 (de) Verbindungen die p-selectin binden

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.

B15K Others concerning applications: alteration of classification

Ipc: C07K 7/06 (2006.01), A61K 47/64 (2017.01), C07K 5/